PMID- 15031611
OWN - NLM
STAT- MEDLINE
DCOM- 20040510
LR  - 20131121
IS  - 1018-2438 (Print)
IS  - 1018-2438 (Linking)
VI  - 133
IP  - 4
DP  - 2004 Apr
TI  - Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in 
      the treatment of seasonal allergic rhinitis: a randomized, double-blind, 
      placebo-controlled study.
PG  - 371-9
AB  - BACKGROUND: Few randomized studies have compared loratadine to ebastine in the 
      symptomatic treatment of seasonal allergic rhinitis (SAR) patients. METHODS: This 
      double-blind, placebo-controlled, randomized, parallel-group, comparative trial 
      compared the efficacy and safety of ebastine 20 mg (E20), loratadine 10 mg (L10) 
      and placebo (P), administered once daily, in the control of SAR symptoms over a 
      2-week period. An additional 2-week treatment period was included in order to 
      check sustained efficacy and tolerability. RESULTS: A total of 703 patients were 
      enrolled: 282 patients in the E20 group, 279 in the L10 group and 142 in the P 
      group. E20 showed a greater decrease from baseline in the main efficacy variable 
      (mean daily reflective total symptom score) than L10 (p = 0.0018) or P (p = 
      0.0024), whereas the difference between L10 and P was not significant. Moreover, 
      reductions from baseline in all composite/individual daily reflective rhinitis 
      symptom scores were significantly larger in patients receiving E20 than in 
      patients receiving L10 or P. Most significant differences between E20 and L10 or 
      P were maintained after 4 weeks of treatment. Overall, all treatments were safe 
      and well tolerated. There was no significant difference in the percentage of 
      patients who reported one or more adverse events (AEs) between the groups, and 
      most AEs were mild to moderate (89.9%). CONCLUSIONS: E20 given once daily for 2 
      weeks was more effective in the treatment of SAR symptoms than L10 or P. E20 also 
      showed a sustained efficacy after 4 weeks of treatment, and overall was well 
      tolerated and proved safe.
CI  - Copyright 2004 S. Karger AG, Basel
FAU - Ratner, P
AU  - Ratner P
AD  - Sylvana Research, San Antonio, TX 78229, USA. phratner@swbell.net
FAU - Hampel, F Jr
AU  - Hampel F Jr
FAU - Van Bavel, J
AU  - Van Bavel J
FAU - Howland, W 3rd
AU  - Howland W 3rd
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20040317
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (Butyrophenones)
RN  - 0 (Histamine H1 Antagonists)
RN  - 0 (Piperidines)
RN  - 7AJO3BO7QN (Loratadine)
RN  - TQD7Q784P1 (ebastine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Butyrophenones/adverse effects/*therapeutic use
MH  - Child
MH  - Double-Blind Method
MH  - Female
MH  - Histamine H1 Antagonists/adverse effects/*therapeutic use
MH  - Humans
MH  - Least-Squares Analysis
MH  - Loratadine/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Piperidines/adverse effects/*therapeutic use
MH  - Rhinitis, Allergic, Seasonal/*drug therapy
EDAT- 2004/03/20 05:00
MHDA- 2004/05/11 05:00
CRDT- 2004/03/20 05:00
PHST- 2003/05/15 00:00 [received]
PHST- 2003/12/03 00:00 [accepted]
PHST- 2004/03/20 05:00 [pubmed]
PHST- 2004/05/11 05:00 [medline]
PHST- 2004/03/20 05:00 [entrez]
AID - 77357 [pii]
AID - 10.1159/000077357 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 2004 Apr;133(4):371-9. doi: 10.1159/000077357. Epub 
      2004 Mar 17.